ECM Weekly (26 Apr 2020) - Kingsoft Cloud, WeDoctor, Akesobio, Kotak Mahindra Bank
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. Akeso...
527 Views
Hansoh Pharma Placement - Good Stock but Valuation and No Lack of Cash Makes It Appear Opportunistic
Hansoh Pharmaceutical (3692 HK) aims to raise up to US$450m to funds its R&D and general working capital requirements. The company was listed...
502 Views
Sino Biopharm (中国生物制药) Placement - Not a Big Deal, Still a Good Company but Relatively Expensive
A shareholder of Sino Biopharmaceutical (1177 HK) is looking to sell about US$297m worth of shares in an accelerated block trade.In this note, we...
425 Views
Akesobio IPO: Valuation Insights
Akeso Biopharma Inc (9926 HK) is a clinical-stage biopharmaceutical company with aims to address global unmet medical needs in oncology, immunology...
550 Views
Akesobio (康方生物) IPO: Expect near Zero Allocation
Akesobio launched book building to raise up to USD 333 million to list in Hong Kong. In our previous note, we discussed that the company features...
715 Views